Evidence map›Paper›PMID 24388389›Full record

ArticleBiomaterials2014

Tunable staged release of therapeutics from layer-by-layer coatings with clay interlayer barrier.

Jouha Min, Richard D Braatz, Paula T Hammond

Abstract read
In one paragraph

Article in Biomaterials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Designing the Next Generation of Biomaterials through Nanoengineering.Advanced materials (Deerfield Beach, Fla.) · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Nanomedicine strategies to counteract cancer stemness and chemoresistance.Exploration of targeted anti-tumor therapy · 2023
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jouha MinDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02139, USA.
Richard D BraatzDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Paula T HammondDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02139, USA. Electronic address: hammond@mit.edu.

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Michael Birnbaum · 1985 to 2026
$93.9M
Nanoscale Electrostatic Assemblies for Multi-Agent Drug Delivery fromR01AG029601 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HAMMOND, PAULA T · 2007 to 2011
$1.9M
NCI NIH HHS P30 CA014051NCI NIH HHS P30-CA14051NIA NIH HHS 5R01AG029601-03NIA NIH HHS R01 AG029601
6 · The paper itself

Abstract

In developing new generations of coatings for medical devices and tissue engineering scaffolds, there is a need for thin coatings that provide controlled sequential release of multiple therapeutics while providing a tunable approach to time dependence and the potential for sequential or staged release. Herein, we demonstrate the ability to develop a self-assembled, polymer-based conformal coating, built by using a water-based layer-by-layer (LbL) approach, as a dual-purpose biomimetic implant surface that provides staggered and/or sustained release of an antibiotic followed by active growth factor for orthopedic implant applications. This multilayered coating consists of two parts: a base osteoinductive component containing bone morphogenetic protein-2 (rhBMP-2) beneath an antibacterial component containing gentamicin (GS). For the fabrication of truly stratified composite films with the customized release behavior, we present a new strategy-implementation of laponite clay barriers-that allows for a physical separation of the two components by controlling interlayer diffusion. The clay barriers in a single-component GS system effectively block diffusion-based release, leading to approximately 50% reduction in bolus doses and 10-fold increase in the release timescale. In a dual-therapeutic composite coating, the top GS component itself was found to be an effective physical barrier for the underlying rhBMP-2, leading to an order of magnitude increase in the release timescale compared to the single-component rhBMP-2 system. The introduction of a laponite interlayer barrier further enhanced the temporal separation between release of the two drugs, resulting in a more physiologically appropriate dosing of rhBMP-2. Both therapeutics released from the composite coating retained their efficacy over their established release timeframes. This new platform for multi-drug localized delivery can be easily fabricated, tuned, and translated to a variety of implant applications where control over spatial and temporal release profiles of multiple drugs is desired.

Indexed as

Delayed-Action Preparations3T3 CellsAluminum SilicatesAnimalsBone Morphogenetic Protein 2Cell DifferentiationCell LineCell SurvivalClayCoated Materials, BiocompatibleDrug CarriersDrug Resistance, BacterialGentamicinsMicePolymersStaphylococcus aureusAluminum SilicatesBmp2 protein, mouseBone Morphogenetic Protein 2ClayCoated Materials, BiocompatibleDelayed-Action PreparationsDrug CarriersGentamicinsPolymersAntibacterialBMP (bone morphogenetic protein)BoneControlled drug releaseLayer-by-layerSilicate

Identifiers

PMID24388389
PMCPMC3951715

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.